467 related articles for article (PubMed ID: 33751752)
1. Safety and Efficacy of Cetuximab-Based Salvage Chemotherapy After Checkpoint Inhibitors in Head and Neck Cancer.
Cabezas-Camarero S; Cabrera-Martín MN; Merino-Menéndez S; Paz-Cabezas M; García-Barberán V; Sáiz-Pardo Sanz M; Iglesias-Moreno M; Alonso-Ovies A; Pérez-Segura P
Oncologist; 2021 Jun; 26(6):e1018-e1035. PubMed ID: 33751752
[TBL] [Abstract][Full Text] [Related]
2. Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Suzuki S; Toyoma S; Kawasaki Y; Koizumi K; Iikawa N; Shiina K; Endo T; Abe T; Kouga T; Yamada T
Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833369
[No Abstract] [Full Text] [Related]
3. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
4. Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Takeshita N; Enokida T; Okano S; Fujisawa T; Wada A; Sato M; Tanaka H; Tanaka N; Onaga R; Hoshi Y; Sakashita S; Ishii G; Tahara M
Oral Oncol; 2023 Dec; 147():106615. PubMed ID: 37931493
[TBL] [Abstract][Full Text] [Related]
5. Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer.
Park SE; Lee SH; Ahn JS; Ahn MJ; Park K; Sun JM
J Thorac Oncol; 2018 Jan; 13(1):106-111. PubMed ID: 29101058
[TBL] [Abstract][Full Text] [Related]
6. Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma.
Chen TH; Pan YY; Lee TL; Wang LW; Tai SK; Chu PY; Lo WL; Wu CH; Yang MH; Chang PM
BMC Cancer; 2022 Dec; 22(1):1336. PubMed ID: 36539738
[TBL] [Abstract][Full Text] [Related]
7. First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial.
Guo Y; Luo Y; Zhang Q; Huang X; Li Z; Shen L; Feng J; Sun Y; Yang K; Ge M; Zhu X; Wang L; Liu Y; He X; Bai C; Xue K; Zeng Y; Chang X; Chen W; Lin T
Eur J Cancer; 2021 Oct; 156():35-45. PubMed ID: 34418665
[TBL] [Abstract][Full Text] [Related]
8. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Saleh K; Daste A; Martin N; Pons-Tostivint E; Auperin A; Herrera-Gomez RG; Baste-Rotllan N; Bidault F; Guigay J; Le Tourneau C; Saada-Bouzid E; Even C
Eur J Cancer; 2019 Nov; 121():123-129. PubMed ID: 31574417
[TBL] [Abstract][Full Text] [Related]
9. Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck.
Trieu V; Pinto H; Riess JW; Lira R; Luciano R; Coty J; Boothroyd D; Colevas AD
Oncologist; 2018 Jul; 23(7):764-e86. PubMed ID: 29540603
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Paclitaxel Combined With Cetuximab for Head and Neck Squamous Cell Carcinoma.
Okada T; Okamoto I; Sato H; Ito T; Miyake K; Tsukahara K
In Vivo; 2021; 35(2):1253-1259. PubMed ID: 33622928
[TBL] [Abstract][Full Text] [Related]
11. Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancer.
Fuchs H; Pammer J; Minichsdorfer C; Posch D; Kornek G; Aretin MB; Fuereder T
Med Oncol; 2018 Feb; 35(3):32. PubMed ID: 29411154
[TBL] [Abstract][Full Text] [Related]
12. A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer.
Desilets A; Pfister DG; Stein S; Wong W; Sherman EJ; Fetten J; Hung TKW; Kriplani A; Dunn LA; Ho AL; Michel LS
Oral Oncol; 2024 Jul; 154():106861. PubMed ID: 38795600
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck: a single-center retrospective study.
Kurosaki T; Mitani S; Tanaka K; Suzuki S; Kanemura H; Haratani K; Fumita S; Iwasa T; Hayashi H; Yoshida T; Ishikawa K; Kitano M; Otsuki N; Nishimura Y; Doi K; Nakagawa K
Anticancer Drugs; 2021 Jan; 32(1):95-101. PubMed ID: 32976215
[TBL] [Abstract][Full Text] [Related]
14. Palliative chemotherapy with or without cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck: Indian tertiary care retrospective analysis.
Bahl A; Bhatia K; Choudhary P; Singhla S; Shrivastava G; Bal J; Anand AK; Chaturvedi H; Dua B
Head Neck; 2020 May; 42(5):955-962. PubMed ID: 31916340
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of weekly paclitaxel, carboplatin, and cetuximab in head and neck cancer patients with incurable disease.
Narveson L; Kathol E; Rockey M; Henry D; Grauer D; Neupane P
Med Oncol; 2016 Oct; 33(10):107. PubMed ID: 27568333
[TBL] [Abstract][Full Text] [Related]
16. Activity of weekly paclitaxel-cetuximab chemotherapy in unselected patients with recurrent/metastatic head and neck squamous cell carcinoma: prognostic factors.
Bernad IP; Trufero JM; Urquizu LC; Pazo Cid RA; de Miguel AC; Agustin MJ; Lanzuela M; Antón A
Clin Transl Oncol; 2017 Jun; 19(6):769-776. PubMed ID: 28120324
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients.
Jiménez B; Trigo JM; Pajares BI; Sáez MI; Quero C; Navarro V; Llácer C; Medina L; Rueda A; Alba E
Oral Oncol; 2013 Feb; 49(2):182-5. PubMed ID: 23026069
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody.
Koyama T; Kiyota N; Boku S; Imamura Y; Shibata N; Satake H; Tanaka K; Hayashi H; Onoe T; Asada Y; Yamazaki T; Nose T; Ohata S; Nagatani Y; Kimbara S; Funakoshi Y; Teshima M; Shinomiya H; Minami H
ESMO Open; 2024 Jun; 9(6):103476. PubMed ID: 38833968
[TBL] [Abstract][Full Text] [Related]
19. Palliative weekly chemotherapy along with cetuximab in recurrent and metastatic head and neck cancers: a retrospective analysis.
Rangaraju RR; Sharma JB; Dewan AK; Anand AK; Sheh R; Jena A; Chaturvedi AK
Indian J Cancer; 2012; 49(1):1-5. PubMed ID: 22842160
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and toxicity of cetuximab with chemotherapy in recurrent and metastatic head and neck cancer: A prospective observational study.
Tiwari S; Goel V; John MC; Patnaik N; Doval DC
Indian J Cancer; 2016; 53(4):487-492. PubMed ID: 28485336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]